These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7551660)

  • 1. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis.
    Barrera P; Haagsma CJ; Boerbooms AM; Van Riel PL; Borm GF; Van de Putte LB; Van der Meer JW
    Br J Rheumatol; 1995 Aug; 34(8):747-55. PubMed ID: 7551660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy.
    Barrera P; Boerbooms AM; Janssen EM; Sauerwein RW; Gallati H; Mulder J; de Boo T; Demacker PN; van de Putte LB; van der Meer JW
    Arthritis Rheum; 1993 Aug; 36(8):1070-9. PubMed ID: 8393676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells.
    Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Baggiolini M; Gerber NJ
    Br J Rheumatol; 1995 Jul; 34(7):602-9. PubMed ID: 7670776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
    Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
    J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate.
    Barrera P; Boerbooms AM; Demacker PN; van de Putte LB; Gallati H; van der Meer JW
    Br J Rheumatol; 1994 Nov; 33(11):1017-24. PubMed ID: 7981988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine antagonists in aged subjects and their relation with cellular immunity.
    Catania A; Airaghi L; Motta P; Manfredi MG; Annoni G; Pettenati C; Brambilla F; Lipton JM
    J Gerontol A Biol Sci Med Sci; 1997 Mar; 52(2):B93-7. PubMed ID: 9060965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy.
    Haagsma CJ; van Riel PL; de Rooij DJ; Vree TB; Russel FJ; van't Hof MA; van de Putte LB
    Br J Rheumatol; 1994 Nov; 33(11):1049-55. PubMed ID: 7981992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis.
    Nisar M; Carlisle L; Amos RS
    Br J Rheumatol; 1994 Jul; 33(7):651-4. PubMed ID: 7912633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.
    Salaffi F; Carotti M; Cervini C
    Clin Rheumatol; 1995 Jul; 14(4):458-63. PubMed ID: 7586985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate.
    Crilly A; McInness IB; McDonald AG; Watson J; Capell HA; Madhok R
    J Rheumatol; 1995 Feb; 22(2):224-6. PubMed ID: 7738942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes.
    Mangge H; Kenzian H; Gallistl S; Neuwirth G; Liebmann P; Kaulfersch W; Beaufort F; Muntean W; Schauenstein K
    Arthritis Rheum; 1995 Feb; 38(2):211-20. PubMed ID: 7848311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis.
    Dessein PH; Joffe BI
    Clin Exp Rheumatol; 2006; 24(2):161-7. PubMed ID: 16762151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.
    Dougados M; Combe B; Cantagrel A; Goupille P; Olive P; Schattenkirchner M; Meusser S; Paimela L; Rau R; Zeidler H; Leirisalo-Repo M; Peldan K
    Ann Rheum Dis; 1999 Apr; 58(4):220-5. PubMed ID: 10364900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment.
    Seitz M; Dayer JM
    Rheumatology (Oxford); 2000 Jun; 39(6):637-45. PubMed ID: 10888709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs.
    Seitz M; Loetscher P; Dewald B; Towbin H; Baggiolini M
    J Rheumatol; 1997 Aug; 24(8):1471-6. PubMed ID: 9263137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
    Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy.
    Sakamoto N; Hara S; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kakugawa T; Yamaguchi H; Obase Y; Kushima H; Ishii H; Noguchi S; Kido T; Kobayashi T; Soejima Y; Yoshioka S; Ishimatsu Y; Yatera K; Kadota JI; Mukae H
    Tohoku J Exp Med; 2019 Jul; 248(3):209-216. PubMed ID: 31366819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine.
    Danis VA; Franic GM; Rathjen DA; Laurent RM; Brooks PM
    Ann Rheum Dis; 1992 Aug; 51(8):946-50. PubMed ID: 1358037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
    Capell HA; Madhok R; Porter DR; Munro RA; McInnes IB; Hunter JA; Steven M; Zoma A; Morrison E; Sambrook M; Wui Poon F; Hampson R; McDonald F; Tierney A; Henderson N; Ford I
    Ann Rheum Dis; 2007 Feb; 66(2):235-41. PubMed ID: 16926184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.